Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 4/20 | 0.50 |
| ▸ | PRKCA | P17252 | 4/20 | 0.49 |
| ▸ | PRKCE | Q02156 | 2/20 | 0.49 |
| ▸ | PRKCQ | Q04759 | 2/20 | 0.49 |
| ▸ | PRKCD | Q05655 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | DGKA | P23743 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1273212 | 0.92 | PRKCA (0.55) | MAPTMAPK1PRKCAPRKCEPRKCQ | |
| SCHEMBL368664 | 0.88 | MAPT (0.62) | MAPTMAPK1LMNAPRKCAPRKCE | |
| SCHEMBL369749 | 0.88 | MAPT (0.62) | MAPTMAPK1LMNAPRKCAPRKCE | |
| SCHEMBL367858 | 0.88 | MAPT (0.62) | MAPTMAPK1LMNAPRKCAPRKCE | |
| SCHEMBL9958966 | 0.88 | MAPT (0.62) | MAPTMAPK1LMNAPRKCAPRKCE | |
| SCHEMBL16612763 | 0.82 | MAPT (0.72) | MAPTMAPK1LMNAPRKCAPRKCE | |
| SCHEMBL16612232 | 0.82 | MAPT (0.72) | MAPTMAPK1LMNAPRKCAPRKCE | |
| SCHEMBL1273757 | 0.81 | PRKCA (0.55) | MAPTMAPK1PRKCAPRKCEPRKCQ | |
| SCHEMBL370806 | 0.81 | USP2 (0.43) | MAPTLMNAALDH1A1MEN1KMT2A | |
| SCHEMBL369784 | 0.80 | PRKCA (0.60) | MAPTMAPK1PRKCAPRKCEPRKCQ |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4384612-A1 | IMPROVED METHOD FOR SMALL RNA PURIFICATION | Mirnagreen S.r.l. (IT) | 2024-06-19 | — | — | EP | disclosed |
| CN-111867634-B | Enhancement of translocation of micro/nanoparticles across mucus layers using alginate oligomers | 阿尔吉法玛公司 | 2024-06-11 | — | — | CN | disclosed |
| CN-117940563-A | Improved small RNA purification process | 米尔纳格林有限责任公司 | 2024-04-26 | — | — | CN | disclosed |
| WO-2023017116-A1 | IMPROVED METHOD FOR SMALL RNA PURIFICATION | MIRNAGREEN S.R.L. (IT) | 2023-02-16 | — | — | WO | disclosed |
| EP-4134432-A1 | IMPROVED METHOD FOR SMALL RNA PURIFICATION | Mirnagreen S.r.l. (IT) | 2023-02-15 | — | — | EP | disclosed |
| CN-114729336-A | Cell-free composition for ATP regeneration and use thereof | 百奥堪引赛股份有限公司 | 2022-07-08 | — | — | CN | disclosed |
| US-20220204967-A1 | METHODS FOR EXTRACTING BIOACTIVE SMALL RNAS FROM PLANTS AND MUSHROOMS | MIRNAGREEN S.R.L. (IT) | 2022-06-30 | — | — | US | disclosed |
| US-20220145282-A1 | Cell-Free Compositions for ATP Regeneration and Uses Thereof | BIOCHEMINSIGHTS, INC. | 2022-05-12 | — | — | US | disclosed |
| EP-3924471-A1 | CELL-FREE COMPOSITIONS FOR ATP REGENERATION AND USES THEREOF | Biocheminsights Inc. (US) | 2021-12-22 | — | — | EP | disclosed |
| EP-3901259-A1 | METHODS FOR EXTRACTING BIOACTIVE SMALL RNAS FROM PLANTS AND MUSHROOMS | Mirnagreen S.r.l. (IT) | 2021-10-27 | — | — | EP | disclosed |
| US-20130251630-A1 | Entrapment of Radionuclides in Nanoparticle Compositions | RIGSHOSPITALET (DK) | 2013-09-26 | — | — | US | disclosed |
| WO-2013135800-A1 | CATIONIC LIPOSOMAL DRUG DELIVERY SYSTEM FOR SPECIFIC TARGETING OF HUMAN CD14+ MONOCYTES IN WHOLE BLOOD | BIONEER A/S (DK) | 2013-09-19 | — | — | WO | disclosed |
| EP-2638896-A1 | Cationic liposomal drug delivery system for specific targeting of human cd14+ monocytes in whole blood | Bioneer A/S (DK) | 2013-09-18 | — | — | EP | disclosed |
| US-20130204121-A1 | NANOPARTICLE-GUIDED RADIOTHERAPY | TECHNICAL UNIVERSITY OF DENMARK (DK) | 2013-08-08 | — | — | US | disclosed |
| EP-2593186-A1 | NANOPARTICLE-GUIDED RADIOTHERAPY | Technical University of Denmark (DK) | 2013-05-22 | — | — | EP | disclosed |
| US-20120213698-A1 | LOADING TECHNIQUE FOR PREPARING RADIONUCLIDE CONTAINING NANOPARTICLES | RIGSHOSPITALET (DK) | 2012-08-23 | — | — | US | disclosed |
| WO-2012079582-A1 | ENTRAPMENT OF RADIONUCLIDES IN NANOPARTICLE COMPOSITIONS | TECHNICAL UNIVERSITY OF DENMARK (DK) | 2012-06-21 | — | — | WO | disclosed |
| EP-2453927-A1 | LOADING TECHNIQUE FOR PREPARING RADIONUCLIDE AND IONOPHORE CONTAINING LIPOSOMES IN WHICH THE IONOPHORE IS 2-HYDROXYQUIONOLINE (CARBOSTYRIL) OR STRUCTURALLY RELATED 2-HYDROXYQUINOLINES | Technical University of Denmark (DK) | 2012-05-23 | — | — | EP | disclosed |
| WO-2012007567-A1 | NANOPARTICLE-GUIDED RADIOTHERAPY | TECHNICAL UNIVERSITY OF DENMARK (DK) | 2012-01-19 | — | — | WO | disclosed |
| WO-2011006510-A1 | LOADING TECHNIQUE FOR PREPARING RADIONUCLIDE AND IONOPHORE CONTAINING LIPOSOMES IN WHICH THE IONOPHORE IS 2-HYDROXYQUIONOLINE (CARBOSTYRIL) OR STRUCTURALLY RELATED 2-HYDROXYQUINOLINES | TECHNICAL UNIVERSITY OF DENMARK (DK) | 2011-01-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120213698-A1 | LOADING TECHNIQUE FOR PREPARING RADIONUCLIDE CONTAINING NANOPARTICLES | LIPG, NPC1L1, CD47 | MAPT 4367/4885MAPK1 4844/4885LMNA 891/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.